Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Heppner

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Bioorganic & Medicinal Chemistry Letters|April 4, 2022
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLCThomas W Gero, David E Heppner, Tyler S Beyett, et al.
Cancer Discovery|May 17, 2019
Single and Dual Targeting of Mutant EGFR with an Allosteric InhibitorCiric To, Jaebong Jang, Ting Chen, et al.
Journal of Medicinal Chemistry|October 20, 2021
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric SitesFlorian Wittlinger, David E Heppner, Ciric To, et al.
Cell|February 29, 2020
A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during AgingHaopeng Xiao, Mark P Jedrychowski, Devin K Schweppe, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Nature Communications|September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitorsYoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Nature Cancer|April 15, 2022
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancerCiric To, Tyler S Beyett, Jaebong Jang, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Bioorganic & Medicinal Chemistry Letters|April 4, 2022
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLCThomas W Gero, David E Heppner, Tyler S Beyett, et al.
Cancer Discovery|May 17, 2019
Single and Dual Targeting of Mutant EGFR with an Allosteric InhibitorCiric To, Jaebong Jang, Ting Chen, et al.
Journal of Medicinal Chemistry|October 20, 2021
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric SitesFlorian Wittlinger, David E Heppner, Ciric To, et al.
Cell|February 29, 2020
A Quantitative Tissue-Specific Landscape of Protein Redox Regulation during AgingHaopeng Xiao, Mark P Jedrychowski, Devin K Schweppe, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Nature Communications|September 24, 2022
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitorsYoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, et al.
Nature Cancer|April 15, 2022
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancerCiric To, Tyler S Beyett, Jaebong Jang, et al.
Pageof 6